BerGenBio

BerGenBio ASA: Invitation to First Quarter 2018 Results Presentation and Webcast

Bergen, Norway, 08 May 2018- BerGenBio ASA (OSE:BGBIO), a clinical-stage

biopharmaceutical company focused on developing bemcentinib (BGB324), a first-in

-class selective small molecule AXL inhibitor, as a potential cornerstone

therapy for multiple cancer indications, will announce its results for the first

quarter 2018 on Tuesday, 15 May 2018. A presentation by BerGenBio's senior

management team will take place at 10:00 am CET at:

Felix Konferansesenter, Bryggetorget 3, 0125 Oslo

The presentation will webcast live and the link will be available at

www.bergenbio.com in the section Investors/Financial Reports. A recording will

be available shortly after the webcast has finished.

The results report and presentation will be available at www.bergenbio.com in

the section: Investors/Financial Reports from 7:00 am CET the same day.

-Ends-

Contacts

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Rune Skeie

CFO, BerGenBio ASA

+47 917 86 513

Media contacts

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

+44 207 638 9571

Forward looking statements

This announcement may contain forward-looking statements, which as such are not

historical facts, but are based upon various assumptions, many of which are

based, in turn, upon further assumptions. These assumptions are inherently

subject to significant known and unknown risks, uncertainties and other

important factors. Such risks, uncertainties, contingencies and other important

factors could cause actual events to differ materially from the expectations

expressed or implied in this announcement by such forward-looking statements.

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.

AI Terminal